# Zinc Deficiency Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

**Authors:** Rahman Hameed Mohammed Abdul, Nafisa Reyaz, Abebe Yigzaw, Bilal Asad Mohammed, Helai Hussaini, Adil Amin, Mohammed Qasim Rauf, Neelum Ali

PMC · DOI: 10.7759/cureus.102684 · Cureus · 2026-01-31

## TL;DR

This study finds that nearly a third of inflammatory bowel disease patients are zinc deficient, with higher rates in Crohn's disease.

## Contribution

The study provides the first meta-analysis quantifying zinc deficiency prevalence in IBD patients using validated biomarkers.

## Key findings

- Zinc deficiency affects 35% of inflammatory bowel disease patients overall.
- Crohn's disease patients show a higher zinc deficiency rate (40%) than ulcerative colitis patients (33%).
- The study highlights the need for routine zinc screening in IBD management.

## Abstract

This systematic review and meta-analysis aimed to comprehensively evaluate the prevalence of zinc deficiency in patients with inflammatory bowel disease (IBD). A systematic literature search was conducted across PubMed/MEDLINE (Medical Literature Analysis and Retrieval System Online), Embase, Scopus, Web of Science, and Cochrane Library from inception to November 2025. Studies reporting zinc deficiency prevalence in IBD patients using validated biomarkers were included. Two independent reviewers performed study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale. Meta-analysis was performed using a random-effects model, with subgroup analyses conducted by IBD subtype. Seven studies comprising 2,403 IBD patients were included. The pooled prevalence of zinc deficiency was 35% (95% CI: 19-52%), with substantial heterogeneity (I² = 98.5%). Subgroup analysis revealed a higher prevalence in Crohn's disease patients (40%, 95% CI: 21-59%) compared to ulcerative colitis patients (33%, 95% CI: 18-51%). These findings underscore the significant burden of zinc deficiency in IBD populations and highlight the need for routine nutritional screening, particularly in Crohn's disease patients. Clinicians should consider zinc assessment as part of comprehensive IBD management, with targeted supplementation for deficient patients to potentially improve clinical outcomes and quality of life.

## Linked entities

- **Diseases:** inflammatory bowel disease (MONDO:0005265), Crohn's disease (MONDO:0005011), ulcerative colitis (MONDO:0005101)

## Full-text entities

- **Diseases:** nausea (MESH:D009325), chronic diarrhea (MESH:D003967), abdominal pain (MESH:D015746), anorexia (MESH:D000855), inflammation (MESH:D007249), Zinc Deficiency (MESH:C564286), immune dysregulation (OMIM:614878), UC (MESH:D003093), mucosal damage (MESH:D052016), IBD (MESH:D015212), protein-losing enteropathy (MESH:D011504), CD (MESH:D003424), malnutrition (MESH:D044342), micronutrient deficiency (MESH:D007153), chronic malabsorption (MESH:D008286)
- **Chemicals:** copper (MESH:D003300), zinc gluconate (MESH:C030691), Zinc (MESH:D015032), zinc sulfate (MESH:D019287), sulfasalazine (MESH:D012460)
- **Species:** gut metagenome (species) [taxon 749906], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951249/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951249/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951249/full.md

---
Source: https://tomesphere.com/paper/PMC12951249